uploads///Chart

Existing Drugs for Renal Cell Carcinoma

By

Nov. 23 2015, Updated 10:08 a.m. ET

Drugs for renal cell carcinoma

As discussed earlier in this series, the U.S. Food and Drug Administration, or FDA, has accepted Bristol-Myers Squibb’s (BMY) supplemental biologics license application, or sBLA, for Opdivo for the treatment of patients with advanced renal cell carcinoma, according to the company’s press release on November 16, 2015.

Article continues below advertisement

Novartis’s Afinitor and Votrient

Novartis’s (NVS) Afinitor is indicated for the treatment of renal cell carcinoma, hormone receptor-positive advanced breast cancer, and neuroendocrine tumors of pancreatic origin. For renal cell carcinoma, Afinitor is indicated for the treatment of patients whose disease has progressed after treatment with VEGF-targeted therapy.

Votrient, a drug indicated for the treatment of advanced renal cell carcinoma and advanced soft tissue sarcoma, was initially under GlaxoSmithKline (GSK) and was transferred to Novartis’ oncology portfolio as a part of the GSK-Novartis deal.

Bayer HealthCare Pharmaceuticals’ Nexavar

Bayer HealthCare Pharmaceuticals’ Nexavar is indicated for the treatment of renal cell carcinoma, hepatocellular carcinoma (a type of liver cancer), and differentiated thyroid carcinoma.

Article continues below advertisement

Pfizer’s Sutent and Torisel

Pfizer’s (PFE) Sutent is indicated for the treatment of advanced renal cell carcinoma, GIST (gastrointestinal stromal tumor), and pancreatic neuroendocrine tumors. Torisel is indicated for the treatment of advanced renal cell carcinoma.

Other drugs

Other drugs for renal cell carcinoma include Genentech’s Avastin, Pfizer’s Inlyta, and Proleukin. Proleukin is a product of Novartis (NVS), with Prometheus Laboratories having rights to distribute, promote, and sell Proleukin in the United States.

To diversify risk, investors can consider ETFs such as the VanEck Vectors Pharmaceutical ETF (PPH), which holds ~5.3% of its total portfolio in Bristol-Myers Squibb, or the iShares US Pharmaceuticals ETF (IHE).

Advertisement

More From Market Realist

  • CONNECT with Market Realist
  • Link to Facebook
  • Link to Twitter
  • Link to Instagram
  • Link to Email Subscribe
Market Realist Logo
Do Not Sell My Personal Information

© Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.